SCHEMBL2675162

SCHEMBL2675162

CN(C)C1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SIGMAR1 Q99720 3/20 0.38
DRD2 P14416 3/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TSHR P16473 1/20 0.38
OPRM1 P35372 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TNKS O95271 1/20 0.38
PARP1 P09874 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.37
NPY1R P25929 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
TRPV4 Q9HBA0 1/20 0.37
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676260 0.88 ACHE (0.45) MEN1KMT2ADRD2NPSR1TSHR
SCHEMBL2677338 0.86 USP14 (0.41) MEN1KMT2ADRD2NPSR1TSHR
SCHEMBL2676349 0.85 ACHE (0.47)
SCHEMBL2675826 0.85 OPRM1 (0.60) SIGMAR1DRD2OPRM1DRD4DRD3
SCHEMBL2676567 0.85 KMT2A (0.42) MEN1KMT2ADRD2NPSR1TSHR
SCHEMBL2676543 0.84 NPSR1 (0.39) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL2676251 0.84 DRD4 (0.44) MEN1KMT2ASIGMAR1DRD2DRD4
SCHEMBL2676392 0.84 MAPK1 (0.45) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL2675569 0.84 ALDH1A1 (0.46) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL1717595 0.83 TACR3 (0.46) OPRM1TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150112-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2010-02-10 EP disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MEN1 3960/4885KMT2A 1850/4885SIGMAR1 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.